Treatment News : Hep C Treatment Helps Stop Cirrhosis Progression in Those Coinfected With HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 10, 2013

Hep C Treatment Helps Stop Cirrhosis Progression in Those Coinfected With HIV

Hepatitis C treatment for those coinfected with HIV who have compensated liver cirrhosis helps prevent liver disease from progressing to decompensated cirrhosis, and it also lowers the risk of death, aidsmap reports. Spanish researchers published in the online edition of Clinical Infectious Diseases the findings of their prospective study of 166 coinfected people who had compensated cirrhosis—when the liver is scarred but still functions—at the outset of the study, which spanned 2001 to 2011. The participants were treated with pegylated interferon and ribavirin for 48 weeks.

A quarter of the participants achieved a sustained virologic response 24 weeks after completing treatment (SVR, considered a cure), and 21 people (21 percent) developed decompensated cirrhosis, which is a later stage of the disease and entails hemorrhaging, liver damage and other complications. Among those who achieved an SVR, 5 percent progressed to decompensated liver disease compared with 27 percent of participants who did not achieve an SVR. With a median follow-up period of 55 months among the cohort, the investigators found that the rate of disease progression was 0.89 per 100 person-years for those who responded to treatment, while those who did not achieve an SVR had a progression rate of 6.4 per 100 person-years.

The probability of progressing to the more serious form of liver disease for those with an SVR one and three years after therapy, respectively, was 0 and 4 percent compared with respective probabilities of 15 and 32 percent for those who did not achieve an SVR.

During the follow-up, there were 24 deaths, comprising 15 percent of the cohort. Five percent of those with an SVR and 22 percent of those without an SVR died. The resulting mortality rate was 0.87 per 100 person years for those with an SVR and 4.1 per 100 person-years for those without.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: compensated cirrhosis, decompensated cirrhosis, aidsmap, HIV, hepatitis C, Clinical Infectious Diseases, pegylated interferon, ribavirin, SVR, sustained virolgic response.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    Poz_Qt
    Columbus
    Ohio


    latinpozdallas
    Dallas
    Texas


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.